New Medication Data Wows Specialists At Annual Meeting
by Pharmacy Life - Published on 21 September 2015
New data presented at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden, and simultaneously published in the
New England Journal of Medicine, has wowed diabetes specialists from around Europe!
The results of the landmark,
7000-patient trial for Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) showed that the medication can significantly reduce the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by
fourteen per cent when added to standard of care in patients with type 2 diabetes (T2D) at high risk of CV events. The study also showed a 38 per cent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke.
Jardiance also resulted in
a lower risk of all-cause mortality (32 per cent reduction) and hospitalisation for heart failure (35 per cent reduction).
‘These results are both novel and exciting for the millions of people living with type 2 diabetes at risk for cardiovascular disease,’ said
Dr Bernard Zinman, Director, Diabetes Centre, Mount Sinai Hospital. ‘Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and
until now no single diabetes medication has been associated with a reduction in mortality. In this study, empagliflozin was shown to prevent one out of three cardiovascular deaths.’
The effect of Jardiance in this trial was observed
on top of standard of care. This means the benefit was seen over and above other treatments patients were already receiving for diabetes and/or cardiovascular disease (such as blood pressure and cholesterol lowering-medications).